News for Ikena Oncology, Inc. (IKNA)

On February 7, 2025, Deep Track Capital, LP (Trades, Portfolio) executed a strategic acquisition of 2,515,513 shares in Ikena Oncology Inc. The transaction was

Transaction Overview On December 31, 2024, BIOTECHNOLOGY VALUE FUND L P (Trades, Portfolio) executed a significant transaction involving Ikena Oncology Inc (IKN

**media[510906]**

Ikena Oncology (IKNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Ikena Oncology ( (IKNA) ) has provided an announcement. Ikena Oncology and Inmagene Biopharmaceuticals have announced a definitive merger agreement, under which the combined company will focus on developing IMG-007, a monoclonal antibody aimed at treating atopic dermatitis and other inflammatory conditions. The transaction involves a private placement raising approximately $175 million, including $75 million from new and existing investors, and is expected to close in mid-2025. Following the mer

Inmagene Biopharmaceuticals is a clinical stage company focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody with an extended half-life

Ikena Oncology and Inmagene Biopharmaceuticals are merging to focus on developing a monoclonal antibody for atopic dermatitis treatment.

IKNA stock results show that Ikena Oncology beat analyst estimates for earnings per share the second quarter of 2024.

Strong financial position with $145 million in cash and investments at close of second quarter...

Wedbush has downgraded Ikena Oncology (IKNA) to neutral, citing Tuesday’s announcement that the company was discontinuing development of its lead asset, IK-930. Read more here.

Loading... Loading... Shares of Bank of Montreal BMO fell sharply during Wednesday's session after the company reported worse-than-expected second-quarter fina...

Owen Hughes, Accomplished Life Sciences Executive with Deep Experience Across Investing, Operations and Governance, Appointed as Independent Member of the...

The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.10 A.M. ET)..

Read Investment Analysts’ Upgrades for May 11th (ADDYY, AHT, ARCT, ARTNA, ARWR, ASHTY, AZEK, BNCDY, CELH, CLB) at ETF Daily News

Read Analysts’ Downgrades for May 10th (AFRM, ARCH, BCC, BG, BHF, BIIB, DBSDY, DIISY, DLG, E) at ETF Daily News

On Monday morning, 66 companies achieved new lows for the year. Noteable 52-Week Lows: Gilead Sciences (NASDAQ:GILD) was the largest firm on a market ...

/PRNewswire/ -- Omega Funds, ein führendes internationales Unternehmen für Risikokapital im Gesundheitswesen, das sich darauf konzentriert, Patienten...

/PRNewswire/ -- Omega Funds, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced it...

Omega Funds Closes Oversubscribed $650 Million Fund VII to Invest in Transformative Life Science Companies - Adds Mike Powell, Ph.D., as Executive Partner & pro...